Replies to post #118011 on Biotech Values

[oc631]

Are you confusing HCV and HBV? The latter is a very big health problem in Asia; however, DAAs active against HCV are not active against HBV, so the HBV epidemic in Asia does not present a business opportunity for HCV drugs other than the interferons.

Here's an article on just a small slice of SE Asia: Vietnam



http://www.heathersveterans.org/hepatitis.htm



Asian Theater: Southeast Asia has high rates of hepatitis C infection. Currently, between 5 and 8 percent of the Vietnam population is infected with hepatitis C.2 Hepatitis C could have been transmitted to military personnel through tattoos, medical contact, sexual contact, and shared needles

[jq1234]

China has large population infected with HBV and HCV. Estimation varies, but on average about 130m HBV, 40m HCV. China has done a good job in mandating HBV vaccine, thus new infection has been declining; however, China hasn't done much with HCV infection.

Big pharmas are already looking at HCV market in China:

http://www.eurekalert.org/pub_releases/2011-02/t-bsf022411.php

This is a little bit old, but still true:

http://www.hepcchallenge.org/pdf/chronic%20hepatitis%20in%20china_article_reformat1006.pdf